Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis
AUTOR(ES)
Sohn, Joonhong
FONTE
American Society for Clinical Investigation
RESUMO
Steroidal anti-inflammatory drugs induce proteins that inhibit phospholipase A2 (PLA2), including uteroglobin and lipocortin-1 (annexin I). Uteroglobin and lipocortin-1 retain several conserved sequences. Based on these sequences, several nonapeptides (antiflammins) were synthesized. These nonapeptides were shown to have anti-inflammatory effects in vitro and in vivo, possibly by inhibiting PLA2. Subsequent research showed that PLA2 is activated by transglutaminase 2 (TGase 2). We hypothesize here that TGase 2 inhibitors may increase the anti-inflammatory efficacy of inhibiting PLA2 activity. To test this theory, we constructed recombinant peptides containing sequences from pro-elafin (for inhibition of TGase 2), and from lipocortin-1, lipocortin-5, and uteroglobin (for inhibition of PLA2). The recombinant peptides, which had dual inhibitory effects on purified TGase 2 and PLA2, reversed the inflammation of allergic conjunctivitis to ragweed in a guinea pig model. The present work suggests that novel recombinant peptides may be safe and effective agents for the treatment of various inflammatory diseases.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151832Documentos Relacionados
- New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase
- Allergic conjunctivitis and dry eye.
- The consequences of chronic allergic inflammation.
- Brazilian guidelines for the monitoring and treatment of pediatric allergic conjunctivitis
- Eosinophil cationic protein in tears in allergic conjunctivitis.